BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loomba R, Wong R, Fraysse J, Shreay S, Li S, Harrison S, Gordon SC. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment Pharmacol Ther 2020;51:1149-59. [PMID: 32372515 DOI: 10.1111/apt.15679] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Wong RJ, Kachru N, Martinez DJ, Moynihan M, Ozbay AB, Gordon SC. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases. J Clin Gastroenterol 2021;55:891-902. [PMID: 32815873 DOI: 10.1097/MCG.0000000000001409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Wilechansky RM, Simon TG. Editorial: time to eat? Skipping breakfast in metabolic‐associated fatty liver disease. Aliment Pharmacol Ther 2022;55:491-3. [DOI: 10.1111/apt.16755] [Reference Citation Analysis]
3 Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal NH, Lai M. Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD. Hepatol Commun 2021. [PMID: 34970870 DOI: 10.1002/hep4.1841] [Reference Citation Analysis]
4 Rinaldi L, Pafundi PC, Galiero R, Caturano A, Morone MV, Silvestri C, Giordano M, Salvatore T, Sasso FC. Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review. Antioxidants (Basel) 2021;10:270. [PMID: 33578702 DOI: 10.3390/antiox10020270] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
5 Chen VL, Yeh ML, Yang JD, Leong J, Huang DQ, Toyoda H, Chen YL, Guy J, Maeda M, Tsai PC, Huang CF, Yasuda S, Le AK, Dang H, Giama NH, Ali HA, Zhang N, Wang X, Jun DW, Tseng CH, Hsu YC, Huang JF, Dai CY, Chuang WL, Zhu Q, Dan YY, Schwartz M, Roberts LR, Yu ML, Nguyen MH. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma. Hepatol Commun 2021;5:122-32. [PMID: 33437906 DOI: 10.1002/hep4.1606] [Reference Citation Analysis]
6 Wang Y, Crittenden DB, Eng C, Zhang Q, Guo P, Chung D, Fenaux M, Klucher K, Jones C, Jin F, Quirk E, Charlton MR. Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers. Clin Pharmacol Drug Dev 2021. [PMID: 34302449 DOI: 10.1002/cpdd.960] [Reference Citation Analysis]
7 Tarantino G, Citro V, Balsano C. Liver-spleen axis in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2021;15:759-69. [PMID: 33878988 DOI: 10.1080/17474124.2021.1914587] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ajmera V, Nguyen K, Tamaki N, Sharpton S, Bettencourt R, Loomba R. Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2022;15:175628482210938. [DOI: 10.1177/17562848221093869] [Reference Citation Analysis]
9 Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, Fournier C, Staufer K, Stauber RE, Bugianesi E, Younes R, Gaia S, Lupșor-Platon M, Petta S, Shima T, Okanoue T, Mahadeva S, Chan WK, Eddowes PJ, Hirschfield GM, Newsome PN, Wong VW, de Ledinghen V, Fan J, Shen F, Cobbold JF, Sumida Y, Okajima A, Schattenberg JM, Labenz C, Kim W, Lee MS, Wiegand J, Karlas T, Yılmaz Y, Aithal GP, Palaniyappan N, Cassinotto C, Aggarwal S, Garg H, Ooi GJ, Nakajima A, Yoneda M, Ziol M, Barget N, Geier A, Tuthill T, Brosnan MJ, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 2021:gutjnl-2021-324243. [PMID: 34001645 DOI: 10.1136/gutjnl-2021-324243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, Vogl T, Loomba R, Plum-Mörschel L. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2021;54:1150-61. [PMID: 34570916 DOI: 10.1111/apt.16608] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Alqahtani SA, Schattenberg JM. NAFLD in the Elderly. Clin Interv Aging 2021;16:1633-49. [PMID: 34548787 DOI: 10.2147/CIA.S295524] [Reference Citation Analysis]
12 Mun H, So ES. Prevalence of Liver Cirrhosis based on the Metabolic Health and Weight Criteria: Report from the Korea National Health and Nutritional Health Examination Survey (KNANES) Data Analysis. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100721] [Reference Citation Analysis]
13 Harris R, West J, Morling JR. Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Aliment Pharmacol Ther 2020;51:1199-200. [PMID: 32424922 DOI: 10.1111/apt.15714] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Canbay A, Kachru N, Haas JS, Sowa J, Meise D, Ozbay AB. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2020;52:1185-94. [DOI: 10.1111/apt.16016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
15 Caussy C, Aubin A, Loomba R. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Curr Diab Rep 2021;21:15. [PMID: 33742318 DOI: 10.1007/s11892-021-01383-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Møller S, Kimer N, Kronborg T, Grandt J, Hove JD, Barløse M, Gluud LL. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Semin Liver Dis 2021;41:235-47. [PMID: 33992031 DOI: 10.1055/s-0041-1725022] [Reference Citation Analysis]
17 Lee C. Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists? Primary Care Diabetes 2022. [DOI: 10.1016/j.pcd.2022.01.005] [Reference Citation Analysis]
18 Sun H, Feng J, Tang L. Function of TREM1 and TREM2 in Liver-Related Diseases. Cells 2020;9:E2626. [PMID: 33297569 DOI: 10.3390/cells9122626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Expert Rev Gastroenterol Hepatol 2021;:1-14. [PMID: 34493137 DOI: 10.1080/17474124.2021.1974295] [Reference Citation Analysis]
21 Martin K, Hatab A, Athwal VS, Jokl E, Piper Hanley K. Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications. Curr Diab Rep 2021;21:8. [PMID: 33544287 DOI: 10.1007/s11892-021-01377-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Shao SC, Kuo LT, Chien RN, Hung MJ, Lai EC. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews. BMJ Open Diabetes Res Care 2020;8:e001956. [PMID: 33268450 DOI: 10.1136/bmjdrc-2020-001956] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
23 Schreiner AD, Moran WP, Zhang J, Livingston S, Marsden J, Mauldin PD, Koch D, Gebregziabher M. The Association of Fibrosis-4 Index Scores with Severe Liver Outcomes in Primary Care. J GEN INTERN MED. [DOI: 10.1007/s11606-021-07341-z] [Reference Citation Analysis]
24 Kidoguchi S, Kitada K, Nakajima K, Nakano D, Ohsaki H, Kittikulsuth W, Kobara H, Masaki T, Yokoo T, Takahashi K, Titze J, Nishiyama A. Hepatocellular carcinoma induces body mass loss in parallel with osmolyte and water retention in rats. Life Sci 2022;289:120192. [PMID: 34871664 DOI: 10.1016/j.lfs.2021.120192] [Reference Citation Analysis]
25 Ajmera V, Loomba R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab 2021;50:101167. [PMID: 33460786 DOI: 10.1016/j.molmet.2021.101167] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
26 Rabail R, Shabbir MA, Sahar A, Miecznikowski A, Kieliszek M, Aadil RM. An Intricate Review on Nutritional and Analytical Profiling of Coconut, Flaxseed, Olive, and Sunflower Oil Blends. Molecules 2021;26:7187. [PMID: 34885769 DOI: 10.3390/molecules26237187] [Reference Citation Analysis]
27 Saokaew S, Kositamongkol C, Charatcharoenwitthaya P, Srivanichakorn W, Washirasaksiri C, Chaiyakunapruk N, Phisalprapa P. Comparison of noninvasive scoring systems for the prediction of nonalcoholic fatty liver disease in metabolic syndrome patients. Medicine (Baltimore) 2020;99:e23619. [PMID: 33327335 DOI: 10.1097/MD.0000000000023619] [Reference Citation Analysis]
28 Loomba R, Wong R, Fraysse J, Shreay S, Li S, Harrison S, Gordon SC. Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Authors' reply. Aliment Pharmacol Ther 2020;51:1200-1. [PMID: 32424927 DOI: 10.1111/apt.15724] [Reference Citation Analysis]
29 Schreiner AD, Zhang J, Durkalski-Mauldin V, Livingston S, Marsden J, Bian J, Mauldin PD, Moran WP, Rockey DC. Advanced liver fibrosis and the metabolic syndrome in a primary care setting. Diabetes Metab Res Rev 2021. [PMID: 33759300 DOI: 10.1002/dmrr.3452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Ajmera V, Liu A, Bettencourt R, Dhar D, Richards L, Loomba R. The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography. Aliment Pharmacol Ther 2021;54:68-77. [PMID: 33975381 DOI: 10.1111/apt.16392] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Meng L, Goto M, Tanaka H, Kamikokura Y, Fujii Y, Okada Y, Furukawa H, Nishikawa Y. Decreased Portal Circulation Augments Fibrosis and Ductular Reaction in Nonalcoholic Fatty Liver Disease in Mice. Am J Pathol 2021;191:1580-91. [PMID: 34119474 DOI: 10.1016/j.ajpath.2021.06.001] [Reference Citation Analysis]
32 Naeini F, Namkhah Z, Tutunchi H, Rezayat SM, Mansouri S, Jazayeri-Tehrani SA, Yaseri M, Hosseinzadeh-Attar MJ. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial. Trials 2021;22:801. [PMID: 34774104 DOI: 10.1186/s13063-021-05784-7] [Reference Citation Analysis]
33 Hagström H, Bu D, Nasr P, Ekstedt M, Hegmar H, Kechagias S, Zhang N, An Z, Stål P, Scherer PE. Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. Scand J Gastroenterol 2021;56:437-42. [PMID: 33556256 DOI: 10.1080/00365521.2021.1879249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Gu W, Hortlik H, Erasmus HP, Schaaf L, Zeleke Y, Uschner FE, Ferstl P, Schulz M, Peiffer KH, Queck A, Sauerbruch T, Brol MJ, Rohde G, Sanchez C, Moreau R, Arroyo V, Zeuzem S, Welsch C, Trebicka J. Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). Lancet Reg Health Eur 2022;12:100240. [PMID: 34901909 DOI: 10.1016/j.lanepe.2021.100240] [Reference Citation Analysis]